InsiderTrades

Form 4 for CHRS Coherus Oncology, Inc.

Accepted 2023-11-24 00:00:00 ET · period of report 2023-11-22 · accession 0001610717-23-000363 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2023-11-24 2023-11-22 CHRS Lanfear Dennis M Pres, CEO, Dir M - OptEx $1.42 +299.9K 954.8K +46% +$425.9K
D 2023-11-24 2023-11-22 CHRS Lanfear Dennis M Pres, CEO, Dir S - Sale+OE $2.02 -223.1K 731.7K -23% -$450.7K
D 2023-11-24 2023-11-22 CHRS Lanfear Dennis M Pres, CEO, Dir M - OptEx $0.00 -299.9K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-11-22 M A 41,000 $1.42 695,853 D — —
2 Common Common Stock 2023-11-22 S D 223,100 $2.02 731,693 D — — (F3) This transaction was executed in multiple trades at prices ranging from $2.000 to $2.055. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
3 Common Common Stock 2023-11-22 M A 258,940 $1.42 954,793 D — —
4 Derivative Stock Option (Right to Buy) 2023-11-22 M D 299,940 $0.00 0 D $1.42 · — to 2023-11-22 299,940 Common Stock (F6) The underlying shares subject to the option vested and became exercisable in successive, equal monthly installments over four years measured from July 20, 2013.